The epidemic of cardiovascular disease (CVD) is a global phenomenon, and the magnitude of its increase in incidence and prevalence in low- and middle-income countries (LMIC) has potentially major implications for those high-income countries that characterize much of the developed world. Cardiovascular disease remains the leading cause of death in the world and approximately 80% of all cardiovascular-related deaths occur in LMIC and at a younger age in comparison to high-income countries. The economic impact in regard to loss of productive years of life and the need to divert scarce resources to tertiary care is substantial. The ‘epidemiologic transition’ provides a useful framework for understanding changes in the patterns of disease as a result of societal and socioeconomic developments in different countries and regions of the world. A burning but as yet unanswered question is whether gains made over the last four decades in reducing cardiovascular mortality in high-income countries will be offset by changes in risk factor profiles, and in particular obesity and diabetes. Much of the population attributable risk of myocardial infarction is accountable on the basis of nine modifiable traditional risk factors, irrespective of geography. Developing societies are faced with a hostile cardiovascular environment, characterized by changes in diet, exercise, the effects of tobacco, socioeconomic stressors, and economic constraints at both the national and personal level in addition to exposure to potential novel risk factors and perhaps a genetic or programmed foetal vulnerability to CVD in later life. There are major challenges for primary and secondary prevention including lack of data, limited national resources, and the lack of prediction models in certain populations. There are two major approaches to prevention: public health/community-based strategies and clinic-based with a targeted approach to high-risk patients and combinations of these. There are concerns that in comparison with communicable diseases, cardiovascular and chronic diseases have a relatively low priority in the global health agenda and that this requires additional emphasis.

The human race has had long experience and a fine tradition in surviving adversity, but we now face a task for which we have little experience, the task of surviving prosperity Alan Gregg 1890-1957, Rockefeller Foundation.
within the umbrella of the rapidly expanding newly industrialized nations.

This review will focus upon the changing demographics of CVD; the features of the ‘epidemiologic transition’ which provides a basis for understanding patterns of disease in different regions of the world and in relationship to societal changes; a discussion of the marked regional differences in disease prevalence and explanations for these, including the presence of traditional and novel risk factors, in addition to highlighting different approaches to primary and secondary prevention.

Demographics: the magnitude of the burden of disease

The facts are unequivocal and disturbing—CVD remains the leading cause of death in the world, far outstripping deaths due to malaria, HIV/AIDS, and tuberculosis. Approximately 80% of the 35 million deaths annually attributable to chronic diseases and a similar proportion of the approximately 16.7 million deaths due to CVD occur in low- and middle-income countries (LIMIC); defined as a gross national income per capita of less than $10,066 US dollars per annum in 2004. Moreover, CVD occurs at a younger age and although this might reflect to some extent a demographic artefact due to the lower age distribution in LIMIC, the personal and macro-economic implications for the workforce and national productivity are profound. A recent study of five countries emphasizes that a much higher proportion of deaths occur in the working age population in Brazil, India, and South Africa in contrast to the USA and Portugal. Despite limitations in regard to the quality of data collection, the potential consequences of the burden of CVD falling upon the ‘breadwinners’ of the community are sobering; LIMIC are faced with a dual burden of communicable and degenerative diseases which require tertiary care and a consequent diversion of limited resources. In conjunction with the loss of productive years of life, the consequences lead to economic constraints with an impact on both the private and the public sectors.

Moreover, the demographic tide is inexorably shifting, and it is estimated that by 2010, 70% of the world’s elderly will live in LIMIC and the trend towards urbanization will accelerate. Other studies project that the increase in mortality due to coronary heart disease and stroke will be approximately three-fold higher in developing countries in comparison to the developed world and in relationship to societal changes; a discussion of the marked regional differences in disease prevalence and explanations for these, including the presence of traditional and novel risk factors, in addition to highlighting different approaches to primary and secondary prevention.

The epidemiological transition

The epidemiological transition provides a useful framework for understanding changes in the patterns of disease as a result of socioeconomic and demographic developments. The epidemiologic transition consists of four basic stages: pestilence and famine, receding pandemics, degenerative and man-made diseases, and the phase of delayed degenerative diseases (Figure 1A and B).

Stage 1: the age of pestilence and famine

This has characterized much of human development throughout the course of history with cardiac disease (rheumatic and nutritional) accounting for less than 10% of total deaths (Figure 1A). In regions such as the USA and Europe, the transition into the next phase (Stage 2) occurred in the late 18th and throughout the 19th century, but in many developing countries infectious and post-infectious circulatory disorders continue to exact a major toll and are neglected in the overall global agenda for the research and control of CVD.

Stage 2: the age of receding pandemics

In Phase 2, improved nutrition and public health results in increased longevity, less deaths due to infections and malnutrition, and the emergence of hypertension, stroke, and coronary disease, although rheumatic heart disease is still prevalent. In this phase, stroke is primarily haemorrhagic, presumably due to uncontrolled hypertension. Examples of this phase are the USA in the early part of the 20th century and parts of China and India today.

Stage 3: the age of degenerative and man-made diseases

In stage 3, improvements in socioeconomic status and urbanization are accompanied by marked changes in risk factors including increased fat and caloric intake, tobacco use, and reduced levels of exercise leading to hypertension, obesity, and atherosclerosis (Figure 1B). Cardiovascular deaths account for 35–65% of all deaths, and exceed death rates due to infections and malnutrition. The commonest mode of death in stage 3 is ischaemic heart disease and stroke, and in some countries haemorrhagic stroke is still more frequent than ischaemic stroke. Examples of Phase 3 are the USA during 1930 to 1965, Western Europe approximately 10 years later, and many parts of China, India, the Middle East, Eastern Europe, and Latin America today.

Interestingly, the emergence of cardiovascular and ischaemic heart disease during Phase 3 is primarily seen among the better educated and more affluent as shown in the INTERHEART study of a relatively small number of black Africans with myocardial infarction. In contrast, among whites and coloureds, myocardial infarction was more commonly associated with lower socioeconomic status.
Stage 4: the age of delayed degenerative diseases

Stage 4 or the age of delayed degenerative diseases, is currently the situation in most high income and highly industrialized nations of the world (Figure 1B).5,10,12 Life expectancy is greater than 70 years; leading causes of mortality are CVD and cancer, and the dominant forms of cardiovascular death are ischaemic heart disease, ischaemic stroke, and more recently congestive heart failure. In this phase of the transition, premature coronary artery disease tends to occur in patients of lower socioeconomic status since the benefits of risk factor reduction, secondary prevention, and access to evidence-based therapies and new technologies tend to be more widely implemented among the societally advantaged.13,22–25 Among the higher socioeconomic classes, coronary artery disease is predominately a disease of the elderly. Examples of this are provided by data from the Women’s Heart Study in which higher levels of education and income among apparently healthy female professionals were associated with a lower rate of cardiovascular events over a 10-year period.23 Similarly, in a high-income country such as Canada, which also has universal healthcare, CVD mortality rates are lowest among the most affluent with evidence of an announced gradient based upon income.25

Is there a stage 5?
The last four decades have witnessed a gratifying fall in the USA of 2% per year in the age-adjusted coronary heart disease mortality and 3% per year in stroke mortality. This is attributable mainly to control of risk factors and to a lesser extent upon new therapeutic advances.26 Nonetheless, in the wake of increasing prosperity and urbanization the epidemic of obesity, diabetes, and hypertension is now a world-wide phenomenon.27 In addition, the decline in smoking rates is levelling off in some countries, and rates of detection and treatment of hypertension have not

---

### Figure 1 Stages of epidemiologic transition.

<table>
<thead>
<tr>
<th>Stage 1</th>
<th>Pestilence and famine</th>
</tr>
</thead>
<tbody>
<tr>
<td>Description</td>
<td>Life expectancy</td>
</tr>
<tr>
<td>Malnutrition</td>
<td>35 years</td>
</tr>
<tr>
<td>Infectious diseases</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Stage 2</th>
<th>Receding pandemics</th>
</tr>
</thead>
<tbody>
<tr>
<td>Description</td>
<td>Life expectancy</td>
</tr>
<tr>
<td>Improved nutrition and public health</td>
<td>50 years</td>
</tr>
<tr>
<td>Chronic disease</td>
<td></td>
</tr>
<tr>
<td>Hypertension</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Stage 3</th>
<th>Degenerative and man-made diseases</th>
</tr>
</thead>
<tbody>
<tr>
<td>Description</td>
<td>Life expectancy</td>
</tr>
<tr>
<td>↑ fat and caloric intake</td>
<td>&gt;60 years</td>
</tr>
<tr>
<td>Tobacco use</td>
<td></td>
</tr>
<tr>
<td>Chronic disease deaths</td>
<td></td>
</tr>
<tr>
<td>&gt; infections, malnutrition</td>
<td></td>
</tr>
<tr>
<td>Stroke — Haemorrhagic</td>
<td></td>
</tr>
<tr>
<td>Ischaemic</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Stage 4</th>
<th>Delayed degenerative diseases</th>
</tr>
</thead>
<tbody>
<tr>
<td>Description</td>
<td>Life expectancy</td>
</tr>
<tr>
<td>Leading causes of mortality CV and cancer deaths</td>
<td>&gt;70 years</td>
</tr>
<tr>
<td>Prevention and Tx delays onset</td>
<td></td>
</tr>
<tr>
<td>Age-adjusted CV death reduced</td>
<td></td>
</tr>
</tbody>
</table>

* Greater in high socioeconomic groups
** Younger patient—lower socioeconomic status
Elderly—higher socioeconomic status

Omran: Milbank Mem Fund Q, 1971
Olshansky: Milbank Mem Fund Q, 1986
Gaziano: Circ, 2003
Yusuf: Circ, 2005
in part different stages of the epidemiological transition, even within the same country, e.g. rates of coronary heart disease and stroke in rural vs. urban populations in China; the disparities in India; and in cardiovascular mortality rates between countries which were formerly part of the Eastern Bloc. In this respect, declining rates have been noted in the Czech Republic, Poland, and Hungary, but rates have increased in the Ukraine, Bulgaria, and Romania. Regional standards of healthcare allocation of resources are likely major contributory factors in lifestyle and risk factor management. In addition, there is considerable variability in death rates due to ischaemic heart disease vs. stroke, and in the case of the latter, whether ischaemic or haemorrhagic.

In the case of sub-Saharan Africa, despite marked regional differences, much of the continent is at an early phase of the epidemiologic transition with 70% of deaths due to communicable diseases, namely, infections and parasites. In essence, one can consider all of Africa as an epidemiological transition spanning the spectrum from Phase 1 to Phase 4 in different countries and among different ethnic groups. Recent data from South Africa are interesting and perhaps provide a window into a future epidemic. The Heart of Soweto Study in predominantly urban, black South Africans, drew attention to the rising incidence of risk factors in black Africans. In a population with a mean age of 46 years, 78% had greater than one major risk factor, primarily obesity, hypertension, and smoking, although serum cholesterol was elevated in only 14%. In 2006, however, of 1593 new cases of CVD in this study, coronary artery disease was the diagnosis in only 10% and in only blacks this was only 6%. Given the ominous trends in regard to obesity and the increase in other risk factors, it is likely that the coming years will see major increases in the incidence and prevalence of coronary heart disease in South Africa and probably in sub-Saharan Africa as a whole.

The situation in Japan is also intriguing. The Akita-Osaka study of individuals aged 40–69 years demonstrated adverse trends in the terms of myocardial infarction, sudden death, and coronary intervention in men and women, but particularly in men but with little change in the rural population. Nonetheless, the incidence of coronary artery disease in Japan is still approximately three- to four-fold less than in the USA based upon the Minnesota Heart survey and the ARIC studies. Does this imply some degree of genetic protection or is more likely that the levels of risk factors are lower? This remains a plausible and a fascinating unresolved question, but the NI-HAN-SAN study of Japanese men from Japan vs. those who had immigrated many years before to Hawaii or California would suggest that changes in the environment and risk factors eventually dominate in regard to rates of death and myocardial infarction. Nonetheless, the seven countries 25-year follow-up study demonstrates regional variabilities in coronary heart disease mortality rates. For a given level of serum cholesterol mortality rates in the Mediterranean countries of Southern Europe and Japan are significantly less than in Northern Europe, the USA, Serbia, and the inland countries of Southern Europe. To what extent some of these reputed benefits could be the result of the Mediterranean diet is uncertain as are the factors contributing to the ‘French paradox’ which could at least in part be explained by confounding factors or perhaps genetic variabilities.

![Figure 2](https://academic.oup.com/eurheartj/article-abstract/31/6/642/421558)
There is evidence that in the USA and the UK in the early part of the last century, symptomatic coronary artery disease was uncommon or even rare, even allowing for under-diagnosis.\textsuperscript{14,15} It may also have been the case in African-Americans in the 1940s and 1950s\textsuperscript{45,46} at which time the rates were lower in blacks compared with whites in the 1950s in the USA, but rates of CVD and risk factors in African-Americans and Mexican-Americans are now reported to be higher than among whites.\textsuperscript{25} Irrespective, it did not take long, however, for the epidemic to declare its presence in no uncertain manner. Whether the course of the epidemic in Africa will be similar remains to be seen, although the trends in risk factor prevalence are discouraging.

The role of traditional risk factors

A major contribution from the INTERHEART study was the demonstration in a case–control study in 25 countries that over 90% of the population attributable risk of acute myocardial infarction were accounted for by nine modifiable risk factors.\textsuperscript{47–50} These were a history of smoking, diabetes, and hypertension, abdominal obesity, the ApoB/ApoA1 ratio, a psychosocial index, fruit and vegetable intake, exercise, and regular alcohol consumption. Subsequent studies identify that an unhealthy diet accounts for approximately 30% of the population attributable risk of AMI globally\textsuperscript{51} and all forms of tobacco use constitute one of the most powerful global risk factors.\textsuperscript{52} However, the distribution of risk factors might differ among different populations. For example, it seems that in South Africa, obesity and hypertension are a more important problem than elevated cholesterol levels. By contrast in China, elevated blood lipids are common even in ‘normal weight’ people.\textsuperscript{53} This might be important for focused risk factor prevention, e.g. losing weight vs. the administration of a statin, and in particular planning of the composition of the ‘polypill’ per region.\textsuperscript{54} A growing body of evidence in addition to the INTERHEART study in general suggests a strong association between psychosocial stressors in both myocardial infarction and CVD in addition to other chronic diseases.\textsuperscript{45,47,55–57} These and other studies have clearly identified the major targets for primary prevention in the global community. The inverse relationship between socioeconomic status and CVD risk in high-income countries is primarily the result of the increased prevalence and compounding effects of behavioural and psychosocial risk factors in people of lower socioeconomic status. In LIMIC, there are often wide disparities in socioeconomic status and although data in this population science is scarce, it is likely that socioeconomically determined gradients in health are likely to be of major importance in the future.\textsuperscript{24}

The potential role of novel risk factors

Although the rapid growth of CVD in developing countries is fuelled by the emergence of established risk factors, there are other contributors to a hostile cardiovascular environment, which have perhaps been less emphasized (Figure 3).

Air pollution

An explicit American Heart Association scientific statement in 2004 drew attention to the epidemiological data which demonstrated a consistent increased risk for cardiovascular events in relation to both short- and long-term exposure in present day concentrations of ambient particulate matter—a major component of air pollution.\textsuperscript{58} Although not clarified as yet, several plausible mechanistic pathways have been described. It is sobering to note that according to a recent World Bank report of the world’s 20 most polluted cities, 13 of these are in China, 5 in India, 1 in Indonesia, and the other is Cairo in Egypt—all of which are in developing or newly industrialized countries.\textsuperscript{59,60} Nonetheless, the strength of this association between air pollution and CVD requires further evaluation as the potential for confounders is strong.

Climate change

A recent report on managing the effects of climate change from The Lancet and the University College London Institute for Global Health concluded that climate change effects on health will exacerbate inequities between rich and poor.\textsuperscript{61} The major impact of climate change will likely be on communicable diseases, natural disasters, and the risk of malnutrition as opposed to CVD but a secondary impact upon CVD cannot be demonstrated.\textsuperscript{52}

HIV infection

HIV infection impacts paradoxically on cardiovascular risk factors and circulatory disease at the population and individual levels. At the population level, untreated HIV infection is associated with an overall shortening of life expectancy, a reduction of the body mass index, and a fall in the systolic blood pressure of 3 mmHg.\textsuperscript{62,63} These effects can be expected to reduce the incidence of CVD at the population level. In contrast, at the individual level, people living with HIV have an increased incidence of inflammatory circulatory disorders, including macrovascular arteritis, pulmonary hypertension, cardiomyopathy, and tuberculous pericarditis.\textsuperscript{65} Increasing access to retroviral therapies is however changing the landscape for patients in countries with previously limited access to these drugs and as these patients live longer, CVD now ranks as a major cause of death in people living in industrialized countries according to a recent AHA statement. Likely contributing factors are dyslipidaemia, insulin resistance, inflammation, and changes in body fat distribution in addition to drug
toxicities. The potential implications for the future in regard to providing the resources to cope with the dual burden of acute and chronic HIV disease in the developing world are self evident.

The thrifty phenotype and phenotype hypotheses
The ‘thrifty gene’ hypothesis proposed over 50 years ago was based upon the concept that early during our evolutionary history, genes providing efficient fat deposition, salt sensitivity, and insulin resistance would provide survival during periods of famine. In modern society with abundant caloric intake, the genetic substrate could be detrimental resulting in vulnerability to obesity and diabetes. In a nutshell, genes selected for times of adversity now have to function in times of plenty.

The ‘thrifty phenotype’ hypothesis, which may be an adaptive maternal effect, proposes that foetal metabolic adaptations promote survival with the developing organism responding to the maternal—foetal environment which determines an appropriate rate of foetal growth. Subsequent changes in the environment after birth may, however, determine whether previously selected growth trajectories are appropriate or not. The combination of both models has been proposed as the ‘thrifty genotype’ hypothesis.

Others have mounted a persuasive argument that these intuitively appealing concepts are flawed in many aspects and that there is little likelihood that the thrifty gene or thrifty phenotype concept plays any role in regard to the relatively recent adaptation to the current environment. Moreover, the strength of evidence supporting the hypotheses is varied among studies and considered generally to be weak. Nonetheless, recent evidence for more rapid changes within several generations in the genotype linked to new environments, if they impact upon fertility and lifetime reproductive success, i.e. the ‘fertility first’ hypothesis based upon patients with the polycystic ovary syndrome has continued to stimulate interest in regard to both the thrifty gene and phenotype hypotheses.

The combination of a ‘hostile’ cardiovascular environment characterized by a disproportionately ageing population, urbanization, tobacco use, and exposure to second-hand smoke, food and agricultural policies and unfavourable lifestyle behaviours, in addition to the psychosocial/economic stressors involved in rural to urban migration and the challenges of earning a living in struggling economies, among other factors discussed, could unleash a ‘perfect storm’ manifesting as an epidemic of CVD in those regions least able to deal with this (Figure 3).

Challenges for primary and secondary prevention
There is no global solution to the problem, and it is likely that the epidemic will traverse similar paths in different countries, but at different rates, as determined by the pace of development. A universal goal, however, is to utilize our current basis of knowledge to attempt to ‘telescope or abbreviate’ Phase 3 of the epidemiologic transition both in countries with established epidemics and in those at an earlier phase of the transition.

A major challenge is the lack of data and the poor quality of information on causes of death in many but not all regions of the world.

A second hurdle relates to the inability to predict more precisely which groups of patient are at higher risk for CVD, so as to divert scarce resources to the areas of greatest need. Although prediction models have been thoroughly evaluated in the USA and other high-income countries and may be cost effective in the developing world, the development of predictive algorithms for stroke and myocardial infarction in different population with limited facilities is a priority. Moreover, there may be populations of patients at a much higher or lower risk of cardiovascular events than would be predicted from models such as the Framingham model, e.g. Indigenous Australians in whom event rates were two- to three-fold higher than predicted.

The Framingham Study and subsequently the INTERHEART study have identified the important risk factors and as such the targets for modification. Moreover, an analysis of 10 studies across the world in which there has been a decline in CVD mortality, demonstrated that risk factor modification was associated with 44% of the decline in the Netherlands, 50–54% in the USA, and 76% in North Karelia, Finland. New treatments are responsible for 23–47% of the decline in mortality.

The objectives (namely primary and secondary prevention) and the solutions are in many ways obvious, but translating these into countries with limited resources and a surfeit of health issues to be addressed is complex. Two major approaches include public health/community-based strategies targeted at risk factors. These are relatively low cost but require extensive education programs perhaps in addition to regional and national measures, e.g. taxation on tobacco, advertising bans, and legislation in regard to second-hand smoke.

An alternative strategy is clinic-based with the emphasis on targeting high-risk subgroups with lipid-lowering, antihypertensive, and platelet-inhibitor agents. In this respect, the ‘polypill’ has attracted understandable interest and large scale clinical trials are in the planning phase, although a recent multicentre trial from India demonstrated the feasibility and the safety of this approach. Moreover, the cost-dynamics of applying the polypill undoubtedly differ from region to region but are generally considered to be favourable across a range of LIMIC, as is the composition of the pill depending upon the risk factor profile in a particular region. A combination of population-wide and high-risk strategies may be the best approach to treatment and in changing the risk
of the population at large. Moreover, the critically important costs of supporting health professionals (e.g. community nurses), infrastructure (e.g. BP monitors and weight scales), and pathology tests should be emphasized.

The impact of regional cultural, logistic, and economic factors upon the development of preventive strategies is considerable. Compliance is an additional issue and a recent registry highlighted difficulties in this respect among patients from different regions and with different levels of education. Community screening of voluntary adult participants via Heart Awareness Days in Soweto highlighted the lack of awareness of heart disease and the relevance of risk factors. The presence of obesity was 43%, while up to 70% were overweight. The fundamental importance of this finding cannot be overstated. In a culture where low weight is either associated with a historical lack of food or, worse, the modern day epidemic of HIV/AIDS, it is difficult to educate individuals and the wider community about the dangers of excess weight. These obstacles to education and to lifestyle modification may not be as difficult to surmount in parts of Latin America, a region in which obesity is also of paramount impact upon the risks of myocardial infarction.

An ongoing challenge for healthcare delivery in many underdeveloped regions is the lack of resources, the low priority of non-communicable disease in systems geared towards acute care and infectious diseases, and the lack of an integrated infrastructure involving communities, health services, local, and regional institutions. In summary, the three major components of prevention are:

(1) Societal and policy levels to address the upstream social determinants of health, e.g. altering the tobacco, food, and activity environment.
(2) Development of comprehensive and integrated health systems that are based on the primary healthcare philosophy.
(3) Individual prevention, primary, secondary, and tertiary care or acute management.

Summary

In summary, CVD is a substantial and growing problem in most of the developing regions of the world. Key questions to be posed are whether the epidemic can be postponed or abbreviated, what are the costs, how to determine when and how preventive measures should be implemented and to whom. Resources are finite and the need for additional data so as to best focus these are paramount. There is also a need to address the persisting burden of infectious and post-infectious cardiovascular disorders, such as rheumatic fever and Chaga’s disease that remain a major cause of morbidity and mortality among children and young adults throughout the developing world.

Despite this broad canvas and the power of the data, there is nonetheless an impression that the global health agenda is too limited and focused upon communicable diseases. Misperceptions include the understandable fear of global infectious disease epidemics among other factors. In this context, we share the concerns expressed by Fuster et al. in regard to the low priority of cardiovascular and chronic disease in the global health agenda. We also strongly agree with their proposed modification of millennium development goal #6 which could be rephrased to state that the goals are to ‘combat infectious diseases such as HIV/AIDS and malaria along with chronic diseases such as CVD, diabetes, meliitis, and cancer, using an integrated approach’.

Conflict of interest: none declared.

References


